Management of Hodgkin's and non-Hodgkin's lymphomas.
These diseases of the lymphoreticular system with neoplastic alteration of the involved tissues represent different entities and show marked variability in their clinical manifestations, pathologic behavior, prognosis, and response to treatment. New diagnostic, histopathologic, and therapeutic concepts in the past decade have led to significant advances in the care and management of these patients, particularly those with Hodgkin's disease.
D000284:Administration, Oral; D003520:Cyclophosphamide / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D006689:Hodgkin Disease / Q000145:classification / Q000175:diagnosis / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D006801:Humans; D007275:Injections, Intravenous; D008223:Lymphoma / Q000175:diagnosis / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D008466:Mechlorethamine / Q000008:administration & dosage / Q000627:therapeutic use; D011241:Prednisone / Q000008:administration & dosage / Q000627:therapeutic use; D011344:Procarbazine / Q000008:administration & dosage / Q000627:therapeutic use; D011879:Radiotherapy Dosage; D012075:Remission, Spontaneous; D013997:Time Factors; D014750:Vincristine / Q000008:administration & dosage / Q000627:therapeutic use
D011344:Procarbazine; D008466:Mechlorethamine; D014750:Vincristine; D003520:Cyclophosphamide; D011241:Prednisone